Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer cells can compress blood vessels, block entry of drugs

19.02.2004


MGH studies add to understanding of tumor physiology, suggest treatment strategies



A growing tumor needs an increased blood supply for its proliferating cells. But the implications of tumor-related angiogenesis – the growth of new blood vessels – are much more complex than many investigators have realized. Although these new vessels are required to nourish the tumor itself, they are disorganized and abnormal and can actually block therapeutic agents from reaching malignant cells.

In the Feb. 19 issue of Nature, researchers from Massachusetts General Hospital (MGH) describe how proliferating cancer cells compress both blood and lymphatic vessels within tumors. The findings suggest new strategies for improving the success of cancer treatment. Related studies in the February issue of Nature Medicine provide more information about improving the delivery of anticancer drugs to tumor cells.


"We’ve known for several years that internal pressure can make it difficult for many drugs to penetrate into a tumor," says Rakesh Jain, PhD, director of the Edwin Steele Laboratory in the MGH Department of Radiation Therapy, senior author of the Nature and Nature Medicine papers. "Much of our work has focused on fluid pressure within tumors, but this was the first look at solid pressure."

As described in the Nature study, fluid pressure had been assumed to be the force compressing vessels within tumors, but actual fluid pressures inside both tumors and their blood vessels are almost equal. The MGH team investigated whether solid pressure exerted by proliferating cancer cells could compromise blood supply in the same way that stepping on a hose cuts off the flow of water. Using human tumors implanted in mice, the researchers administered diphtheria toxin, which kills tissue from humans but not from mice, to selectively destroy cancer cells.

Analysis of the toxin-treated tumors found that both blood vessels and lymphatic vessels looked much more open than did vessels from untreated tumors, which were largely collapsed. However, although the treated blood vessels appeared to be functioning nearly normally, treated lymphatic vessels were not functional. "Some of the new questions we need to investigate are why decompressed lymphatics do not function, what role vessel decompression may play in tumor growth and metastasis, and how we can use vessel decompression to improve cancer treatment," say Jain, who is Cook Professor of Tumor Biology at Harvard Medical School.

One of the Nature Medicine papers may explain the mechanism of action behind the anti-angiogenesis drug Avastin (bevacizumab), which is currently in clinical trails for FDA approval. In a small group of patients with rectal cancer, the MGH researchers found that Avastin treatment reduces both the number and density of blood vessels within tumors, as well as reducing fluid pressures. Taken with the positive early results of the Avastin trials, this finding is the first clinical confirmation that normalizing the distorted blood supply within tumors could improve the results of therapy.

The second Nature Medicine report uses an advanced imaging technique to examine the structure of the tumor extracellular matrix, composed of connective tissues which block anticancer drugs from reaching tumor cells. The new imaging tool – two-photon fluorescence correlation microscopy – is a significantly better method of measuring the passage of molecules within the matrix. The MGH study revealed that the matrix actually has two components, one that is nearly liquid and a more viscous component that appears to be the most significant barrier to drug delivery. Targeting the viscous matrix component may also improve treatment results.

The Nature study was led by Timothy Padera of the Steele Laboratory. The Nature Medicine Avastin study was led by Christopher Willett, MD, of MGH Radiation Oncology, and the extracellular matrix study was led by George Alexandrakis, PhD, of the Steele Laboratory. All three studies were supported by the National Cancer Institute.


Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $350 million and major research centers in AIDS, cardiovascular research, cancer, cutaneous biology, medical imaging, neurodegenerative disorders, transplantation biology and photomedicine. In 1994, MGH and Brigham and Women’s Hospital joined to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups, and nonacute and home health services.

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>